Neurotransmitter release machinery at the neuromuscular junction (null)

The term "neurotransmitter release at neuromuscular junctions" refers to the process by which the presynaptic terminal of a motor neuron releases the neurotransmitter acetylcholine (ACh) into the synaptic cleft upon arrival of an action potential. This release is triggered by calcium influx through voltage-gated calcium channels, followed by synaptic vesicle fusion and exocytosis. ACh diffuses across the synaptic cleft to activate nicotinic acetylcholine receptors (nAChRs) on the muscle fiber, resulting in depolarization (endplate potential) and muscle contraction[1][4][5]. Many diseases (e.g., myasthenia gravis, Lambert-Eaton syndrome, and various congenital myasthenic syndromes) and drugs (e.g., botulinum toxin, neuromuscular blockers) disrupt this process[1][5]. However, "neurotransmitter release at neuromuscular junctions" describes a physiological process, not a discrete molecular target or therapeutic target as commonly defined for drug development. Therefore, this entry is not a canonical molecular target, but rather a complex process involving multiple proteins, channels, and molecular interactions[1][5]. Key caveat: "Neurotransmitter release at neuromuscular junctions" is not the name of a single molecular target or receptor, but a description of a physiological process involving many component proteins. Canonical molecular targets in this system include the nicotinic acetylcholine receptor, voltage-gated calcium channels (P/Q-type, N-type, L-type), SNARE proteins, and acetylcholinesterase[1][2][4][5]. Naming a single “target” for this process would be scientifically inaccurate.

Other names

neurotransmission at neuromuscular junctionsynaptic vesicle release at NMJacetylcholine release at neuromuscular junctionNMJ transmitter release

Inhibition of acetylcholine release (botulinum toxin) Massive stimulation of ACh release (latrotoxin) Inhibition of ACh breakdown (acetylcholinesterase inhibitors) Antagonism of nicotinic acetylcholine receptors (non-depolarizing neuromuscular blockers) Persistent depolarization of the endplate (depolarizing neuromuscular blockers, e.g., succinylcholine)